by Truveta Research | Jun 26, 2025 | Research, Research Insights
Thimerosal is a preservative contained in some vaccines, which has been used and considered safe for decades. During the June 2025 ACIP meeting, a presentation and vote on the use of thimerosal is scheduled to take place. During the 2024-2025 respiratory virus season,...
by Truveta Research | Jun 11, 2025 | Research, Research Insights
Timely receipt of the MMR vaccine for children has been declining since 2021, with just 76.9% of children receiving the MMR vaccine in 2024 on time. The odds of non-vaccination by age two for measles were higher among male children, children in rural areas, White...
by Truveta Research | May 16, 2025 | Research, Research Insights
Among children in Texas receiving a first measles vaccine prior to two years of life: In March and April 2025, 20.1% of all first measles vaccines were administered to children early (6-11 months). This is 11.5-fold higher than in 2019, when there were international...
by Truveta staff | Sep 28, 2023 | Technology
It’s only September, but COVID-19 and respiratory syncytial virus (RSV) cases are already rising. The latest Truveta Research monitoring report shows that for people over 65, COVID continues to be the most prevalent respiratory virus associated with hospitalizations....
